Analysts at Maxim Group reiterated a Buy rating on AEterna Zentaris Inc. (Nasdaq:AEZS) shares and raised their price target from $7.00 to $10.00, representing a potential upside of 292.15% from the stock’s closing price on Friday of $2.55.
AEterna expects to release top-line results for its pivotal Phase 3 trial of Zoptrex(TM) in the first quarter 2017 and if the results of the trial warrant doing so, to file a new drug application for the oncology compound this year.
The on-going late-stage trial of Zoptrex is evaluating the drug in women with advanced, recurrent or metastatic endometrial cancer who have progressed and who have received one chemotherapeutic regimen with platinum and taxane (either as adjuvant or first-line treatment).
According to AEterna, Zoptrex represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer